Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Twenty-four Week, Open-label, Non-comparative, Multi-center Study to Assess the Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension.

NCT00765947 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00765947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00765947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Twenty-four Week, Open-label, Non-comparative, Multi-center Study to Assess the Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension.
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2008
Completion date
August 31, 2009
Enrollment
256 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension ( mild to moderate)